NeuroEne Therapeutics

NeuroEne Therapeutics is an Israeli neuropharmaceutical startup focused on developing endocannabinoid-based central nervous system modulators targeting two of the most clinically challenging conditions in neurology: treatment-resistant epilepsy and neuropathic pain. The company's therapeutic approach centers on precision modulation of the endocannabinoid system, leveraging the body's own lipid-based signaling pathways to restore neurological balance without the psychoactive liabilities associated with traditional cannabinoid therapies. What sets NeuroEne apart is its proprietary lipid nanoparticle delivery technology, which enables targeted, controlled release of its CNS modulators across the blood-brain barrier with enhanced bioavailability and tissue specificity. This platform addresses one of the fundamental bottlenecks in CNS drug delivery, offering a potentially transformative mechanism for reaching neurological targets that have historically proven difficult to engage pharmacologically.

Headquartered in Tel Aviv, NeuroEne Therapeutics is currently operating at the seed stage following a $6 million funding round, positioning the company in the early-to-mid preclinical phase of development. Israel's well-established neuroscience research ecosystem and deep pharmaceutical talent base provide the company with strong institutional and academic resources as it advances its pipeline. The seed capital is expected to support lead compound optimization, preclinical efficacy and safety studies, and further refinement of its nanoparticle delivery platform. While the company has yet to announce IND filings or clinical milestones, the $6 million raise signals meaningful investor confidence in both the scientific rationale and the founding team's capacity to execute.

NeuroEne Therapeutics represents an important development in the broader neurotechnology landscape, where endocannabinoid system modulation is increasingly recognized as a legitimate and underexplored frontier for CNS therapeutics. Treatment-resistant epilepsy and neuropathic pain collectively affect tens of millions of patients worldwide, with significant unmet need that existing pharmacological options have failed to adequately address. By combining endocannabinoid biology with advanced nanoparticle delivery, NeuroEne is working at the intersection of two rapidly maturing fields, potentially unlocking therapeutic windows that neither approach could achieve independently. If its platform delivers on its preclinical promise, NeuroEne could contribute meaningfully to a new generation of precision CNS therapies and establish Israel as a meaningful contributor to next-generation neuropharmaceutical innovation.